Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.4121
$0.053114.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -37.50% | -98.93% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -37.50% | -98.93% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -37.50% | -98.93% | -- |
| SG&A Expenses | 163.29% | -49.39% | -23.88% | 3.17% | -3.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.87% | -66.09% | -68.12% | -42.11% | -40.10% |
| Operating Income | -15.64% | 65.90% | 68.20% | 38.54% | 40.50% |
| Income Before Tax | 98.12% | 67.36% | 67.66% | 39.19% | 39.64% |
| Income Tax Expenses | -- | 382.94% | 68.56% | 29.69% | -2.58% |
| Earnings from Continuing Operations | 97.25% | 42.10% | 67.56% | 40.22% | 49.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.25% | 42.10% | 67.56% | 40.22% | 49.24% |
| EBIT | -15.64% | 65.90% | 68.20% | 38.54% | 40.50% |
| EBITDA | -15.66% | 65.86% | 68.18% | 38.49% | 40.46% |
| EPS Basic | 99.98% | 94.70% | 87.40% | 72.54% | 97.97% |
| Normalized Basic EPS | 99.27% | 96.98% | 87.33% | 71.81% | 97.57% |
| EPS Diluted | 99.98% | 94.70% | 87.40% | 72.54% | 97.97% |
| Normalized Diluted EPS | 99.27% | 96.98% | 87.33% | 71.81% | 97.57% |
| Average Basic Shares Outstanding | 15,875.99% | 981.84% | 155.22% | 115.68% | 2,386.21% |
| Average Diluted Shares Outstanding | 15,875.99% | 981.84% | 155.22% | 115.68% | 2,386.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |